Crescita Therapeutics Inc remains stable this week as it navigates through its financial results announcements.
Crescita Therapeutics Inc (CTX.TO) has maintained its price stability with no significant fluctuations this week, closing at C$0.79. The stock has shown a year-to-date increase of 64.58%, reflecting a solid performance despite recent financial disclosures.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Crescita Therapeutics Inc
CTX.TO
CTX.TO
Crescita Therapeutics Inc
WealthAwesomeMarket cap
$14.71M
52W high
$0.79
52W low
$0.40
1W change
+0.00%
Beta
-0.14
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CTX's historical volatility
30-Day Vol
16.4%
Annualized
90-Day Vol
80.4%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$0.94
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.84 | C$0.79 – C$0.89 |
| 60 trading days | C$0.89 | C$0.82 – C$0.96 |
| 90 trading days | C$0.94 | C$0.86 – C$1.04 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: With a market cap of approximately C$14.7 million and a focus on therapeutic solutions, Crescita continues to attract attention from investors interested in healthcare innovation, although its profitability metrics indicate ongoing challenges.
Crescita Therapeutics Inc's stock is currently priced at C$0.79.
The stock has a 52-week range of C$0.40 to C$0.79, indicating that it has utilized its full range in the past year, reflecting volatility in investor sentiment.
Bull case
Crescita's recent financial results suggest there’s potential for revenue growth. This could lead to future profitability as the company develops and markets its products in the healthcare sector.
Bear case
However, the company has reported net losses in its recent quarters, raising concerns about its long-term financial viability and ability to achieve profitability in a competitive market.
Price Action Overview
Crescita Therapeutics Inc (CTX.TO) closed at C$0.79 this week, showing no change in its price. The stock has been relatively stable, reflecting a year-to-date gain of 64.58%. Despite the lack of major news, the stock remains within its 52-week range of C$0.40 to C$0.79.
Recent Financial Performance
Crescita has reported its financial results for the last quarters, including a revenue of C$5,955,000 for Q4 and a net loss of C$711,000 for the fiscal year 2025. For Q1 2026, the company reported revenue of C$5,637,000, with a net loss of C$1,160,000. These figures indicate ongoing challenges in achieving profitability.
Technical Picture
From a technical standpoint, Crescita Therapeutics has a 50-day moving average of C$0.75, which is 5.0% above its current price, and a 200-day moving average of C$0.55, indicating a 44.3% increase compared to its price. The stock's beta of -0.14 suggests low volatility relative to the market.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
